---
title: "LENSAR, Inc. (LNSR.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/LNSR.US.md"
symbol: "LNSR.US"
name: "LENSAR, Inc."
industry: "Health Care Equipment"
---

# LENSAR, Inc. (LNSR.US)

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Location | US Market |
| Website | [www.lensar.com](https://www.lensar.com) |

## Company Profile

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System. The company offers LENSAR Laser System which incorpo...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:12.000Z

**Overall: C (0.46)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 80 / 185 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 21.02% |  |
| Net Profit YoY | -209.86% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | -5.25 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 135.93M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 59.14M |  |


**Multi Score**: C

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 3251.75% | A |
| Profit Margin | -87.12% | E |
| Gross Margin | 42.16% | B |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 21.02% | A |
| Net Profit YoY | -209.86% | E |
| Total Assets YoY | 13.20% | B |
| Net Assets YoY | -133.19% | E |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -114.78% | D |
| OCF YoY | 21.02% | A |

#### Operating Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.89 | B |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 117.27% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - LENSAR, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "3251.75%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-87.12%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "42.16%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "21.02%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-209.86%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "13.20%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "-133.19%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-114.78%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "21.02%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "B",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.89",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "117.27%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Inspire Medical (US.INSP) | A | B | A | A | B | A |
| 02 | Delcath (US.DCTH) | C | A | A | A | A | A |
| 03 | Intuitive Surgical (US.ISRG) | A | B | C | A | B | B |
| 04 | Stryker (US.SYK) | A | B | C | C | B | B |
| 05 | Boston Scientific (US.BSX) | B | B | C | C | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.64 | 100/181 | - | - | - |
| PB | -5.25 | 156/181 | 34.53 | 33.73 | 32.71 |
| PS (TTM) | 2.30 | 55/181 | 2.89 | 2.55 | 2.41 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-11-11T05:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 0 | 0% |
| Overweight | 0 | 0% |
| Hold | 2 | 100% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 11.69 |
| Highest Target | 15.00 |
| Lowest Target | 15.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/LNSR.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/LNSR.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/LNSR.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
